| Not Yet Recruiting | Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines NCT07135453 | University of Alabama at Birmingham | Phase 4 |
| Not Yet Recruiting | Opportunistic Pneumococcal Immunisation Trial in MALnutrition NCT06817421 | Nick Fancourt | Phase 4 |
| Recruiting | Serum Collection Study for Assay Development NCT07205289 | GPN Vaccines | Phase 1 |
| Completed | A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults NCT07019909 | Pfizer | Phase 1 |
| Active Not Recruiting | A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant NCT07023081 | Pfizer | Phase 1 |
| Recruiting | Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15 NCT06731374 | University of Oxford | Phase 4 |
| Active Not Recruiting | A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months NCT06622109 | Pfizer | — |
| Completed | A Study to Learn About How a New Pneumococcal Vaccine Works in Children NCT06531538 | Pfizer | Phase 2 |
| Active Not Recruiting | A Study to Learn About How a New Pneumococcal Vaccine Works in Infants NCT06524414 | Pfizer | Phase 2 |
| Active Not Recruiting | A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults NCT06182124 | Pfizer | Phase 1 / Phase 2 |
| Unknown | A Phase I Study of XJ103 in Chinese Healthy Subjects NCT06026748 | Starmab biologics（Shanghai）Co,.ltd | Phase 1 |
| Recruiting | A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccin NCT06044077 | Aimei Vacin BioPharm (Zhejiang) Co., Ltd. | Phase 3 |
| Completed | A Study to Learn About the Safety and Immune Response of 20vPnC in Adults in India. NCT05875727 | Pfizer | Phase 3 |
| Completed | A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance NCT05831124 | Pfizer | Phase 1 |
| Completed | Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9) NCT05633992 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STR NCT05569954 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India NCT05329259 | Pfizer | Phase 4 |
| Completed | A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan NCT05512819 | Pfizer | Phase 3 |
| Completed | Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age NCT05489328 | Pfizer | Phase 1 |
| Completed | A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Y NCT05464420 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7 NCT05393037 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13 NCT05408429 | Pfizer | Phase 3 |
| Completed | 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults NCT04875533 | Pfizer | Phase 3 |
| Completed | Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2 NCT04887948 | Pfizer | Phase 3 |
| Completed | Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036) NCT04633226 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age NCT04642079 | Pfizer | Phase 3 |
| Completed | A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers NCT04525599 | Affinivax, Inc. | Phase 1 |
| Completed | 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants NCT04530838 | Pfizer | Phase 3 |
| Completed | 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants NCT04546425 | Pfizer | Phase 3 |
| Completed | Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age NCT04526574 | Pfizer | Phase 3 |
| Completed | Safety and Immunogenicity of the 'EuPCV15' in Healthy Korean Adults NCT04830358 | EuBiologics Co.,Ltd | Phase 1 |
| Completed | 20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants NCT04379713 | Pfizer | Phase 3 |
| Completed | 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants NCT04382326 | Pfizer | Phase 3 |
| Completed | Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneum NCT03828617 | Pfizer | Phase 3 |
| Completed | Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age NCT03835975 | Pfizer | Phase 3 |
| Completed | A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly NCT03803202 | GlaxoSmithKline | Phase 1 / Phase 2 |
| Completed | Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal NCT03760146 | Pfizer | Phase 3 |
| Completed | Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddler NCT02308540 | PATH | Phase 1 / Phase 2 |
| Completed | Nasopharyngeal Carriage Study in Healthy Kenyan Toddlers NCT02146365 | PATH | — |
| Completed | Post Market Surveillance to Observe Safety of Prevenar13™ in Adults NCT01834222 | Pfizer | — |
| Completed | Hepatitis B Vaccination in Infants NCT01896596 | Public Health England | Phase 4 |
| Completed | A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From NCT01734239 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Pneumococcal Adult Kinetics Study - Understanding the B Cell Response to Pneumococcal Vaccines NCT01432158 | University of Oxford | Phase 3 |
| Completed | Safety Surveillance of Pneumococcal 13-valent Conjugate Vaccine Among Filipinos NCT01396434 | Pfizer | — |
| Completed | Child Pneumococcal Serotype Epidemiology In Greece NCT01111214 | Pfizer | — |
| Completed | Serotype Distribution of Chest X-ray Confirmed Pneumococcal Community Acquired Pneumonia in the Adult Populati NCT01564771 | Pfizer | — |
| Completed | A Study to Assess the Antibody Response of Healthy Chinese Children Who Have Been Vaccinated Previously With 4 NCT01298544 | Pfizer | Phase 4 |
| Completed | Postlicensure Observational Safety Study of 13vPnC Administered to Infants and Toddlers NCT01128426 | Pfizer | — |
| Completed | 13 Valent Pneumococcal Conjugate Vaccine - Follow-on Study NCT01095471 | University of Oxford | Phase 4 |
| Unknown | Multicenter Prospective Evaluation of the Incidence and Serotyes of Invasive Pneumoccocal Disease (IPD) Among NCT00843895 | King Saud University | N/A |
| Completed | Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Childre NCT00743652 | Pfizer | Phase 3 |
| Completed | Disease Burden of Pneumonia, Meningitis and Bacteremia Among Children in Japan: Pneumonet Japan NCT00757575 | Pfizer | — |
| Completed | A Study to Assess the Impact of Pneumococcal Conjugate Vaccination Programme on the Carriage of Pneumococci NCT01040143 | Public Health England | — |
| Completed | Pneumoniae Epidemiology Study in China NCT00471770 | Wyeth is now a wholly owned subsidiary of Pfizer | — |
| Completed | Study Evaluating Prevenar in High-Risk Children NCT00234338 | Wyeth is now a wholly owned subsidiary of Pfizer | — |
| Completed | Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine in Health NCT01767402 | GlaxoSmithKline | Phase 1 |